Director
Institute of Haematology, Royal Prince Alfred Hospital, Australia
Prof. Joy Ho is Clinical Professor, University of Sydney, Director of Haematology and Research at the Institute of Haematology, Royal Prince Alfred Hospital (RPAH). She is also Head of the Myeloma Research Unit at RPAH, and Deputy Clinical Program Director of the Immune Effector Cell Therapy Program. She is the Founding Director of Sydney Blood Cancer Research Institute.
Her research achievements include stewardship of national clinical trials eg Chief Investigator of Australasian Lymphoma and Leukemia Group (ALLG) Myeloma MM16 trial, and multicenter Thalassemia trials. She was RPAH principal investigator of the first multi-centre chimeric antigen receptor-T cell trial in Australia. She has brought multiple clinical trials on novel myeloma and lymphoma therapies, immunotherapy and CAR-T therapy to RPAH and Australia.
She was President of Haematology Society of Australia and New Zealand in 2013-15. She served on the ALLG Scientific and Executive Committees, and chaired the Laboratory Science Committee in 2005-11. In 2017, she was appointed to the Pharmaceutical Benefits Advisory Committee by the Australian Government.
She is Foundation Member and was Deputy Chair of the Medical and Scientific Advisory group of Australian Myeloma Foundation, and member of the International Myeloma Working Group. She was elected to the Board of the International Myeloma Society in 2019, and has served on the Education Committee since 2016. For the American Society of Hematology (ASH), she is invited member of the International Members’ Committee since 2016, and Chair of Metrics Subcommittee for ASH International Programs since 2018.
Awards received include the Albert Baikie Memorial Medal, Kanematsu Memorial Award, Arnott Fellowship in Cancer Research, New York Academy of Sciences Fellowship and Oxford Nuffield Medical Fellowship. She is author of multiple publications on myeloma, lymphoma, cellular immunotherapy and haemoglobinopathies.